N
TEVA icon

Numerai’s Teva Pharmaceuticals TEVA Stock Holding History

Numerai’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Sell
55,858
-11,137
-17% -$371K 0.15% 228
2026
Q1 		$2.02M Buy
+66,995
New +$2.16M 0.2% 153

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Numerai's TEVA Position: Q2 2026 in Review

Numerai reduced its Teva Pharmaceuticals (TEVA) stake by 17% in Q2 2026, selling an estimated $371K and leaving 55,858 shares worth $1.89M. The position accounts for 0.15% of the portfolio, ranked #228.

Numerai first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.02M in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Numerai held 55,858 shares of Teva Pharmaceuticals worth $1.89M as of Q2 2026.
  • Numerai sold 11,137 Teva Pharmaceuticals shares in Q2 2026, an estimated $371K.
  • Teva Pharmaceuticals made up 0.15% of Numerai's portfolio in Q2 2026, its #228 holding.
  • Numerai first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Numerai's Teva Pharmaceuticals position peaked at $2.02M in Q1 2026.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Numerai's 13F filing for Q2 2026, filed 14 Aug 2026.